Chemical modification of specific in situ antibody The natural structure of monoclonal antibodies provides a variety of possibilities for bioconjugation. The chemical-based, specific natural (non-engineered) antibody conjugation has some benefits in thatRead More…
The linker is not only the molecular part of the covalent connection between the antibody and the small molecular payload but also a key element with design properties in targeted drug therapy.Read More…
Innovative Drugs Apoptosis inducer (Bcl-xL inhibitor) The overexpression of anti-apoptotic Bcl-2 family members (including Bcl-xL) is one of the mechanisms by which cancer cells acquire apoptosis resistance. Drugs that block the BH3-bindingRead More…
DNA-damaging Drugs Pyrrolobenzodiazepine and Indolinobenzodiazepine Pyrrolobenzodiazepines (PBD) is a kind of natural product with antineoplastic activity. Their mode of action is selective alkylation in a small groove of DNA, in which guanineRead More…
Antibody-drug conjugate (ADC) is formed by linking monoclonal antibodies targeting specific antigens with small molecular cytotoxic drugs through linkers, which have both the strong killing effect of traditional small molecule chemotherapy andRead More…
With the approval of a number of ADC drugs around the world since 2019, conjugated drugs have developed into one of the hottest tracks in the pharmaceutical industry. Not only traditional ADCRead More…
An antibody-drug conjugate (ADC) is composed of an antibody, a chemical linker, and a small molecular payload, and takes advantage of the specific targeting binding ability of antibody to transport cytotoxic payloadRead More…
Antibody-drug conjugate (ADC) is a new type of biological targeting drug for the cancer treatment, which perfectly combines the high specificity of antibody and the strong lethal power of cytotoxin. With theRead More…
After more than 20 years of development, ADC drug is becoming the main force in cancer treatment, which, compared with traditional chemotherapy, has a wider application scope. However, minimizing ADCs’ non-target toxicityRead More…
At present, ADC drugs are mainly used in the field of tumors, so antigenic targets are required to be highly expressed in tumor cells but with low or no expression in normalRead More…